Q&A: Lymphomas
Expert Answers to HCP Questions on CAR T-Cell Therapies in Lymphoma

Released: March 18, 2021

Expiration: March 17, 2022

Frederick L. Locke
Frederick L. Locke, MD

Activity

Progress
1
Course Completed

In this episode, Frederick L. Locke, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with lymphomas, with questions including:

  • How does the recent approval of lisocabtagene maraleucel and the expanded indication for axicabtagene ciloleucel add to the treatment landscape for DLBCL?
  • Do you see CAR T-cell therapy ever being used in the first-line setting for DLBCL?
  • How should physicians select patients for CAR T-cell therapy vs ASCT in DLBCL?
  • How should physicians sequence CAR T-cell therapy vs BTK inhibitors in MCL?

Presenter:

Frederick L. Locke, MD
Co-Leader
Moffitt Immuno-Oncology Program
Vice Chair and Associate Member
Department of Blood and Marrow Transplant and Cellular Immunotherapy
Research Director and Medical Director
Immune Cell Therapy Program
Moffitt Cancer Center
Tampa, Florida